RxDoctor Payments Data

Rachel Tull Brown

Gerontology · Tualatin, ORNPI 1457924490

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $799 and has fallen 98.3% since, to $14 in 2024.

$975in general payments, 2019–2025

Across 64 payments — averaging $15.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$220
  • Pfizer$165
  • Novo Nordisk$82
  • E.r. Squibb & Sons, L.L.C.$81
  • Actelion Pharmaceuticals US, Inc.$53
  • AstraZeneca$51
  • plus $323 from 12 others

What the payments were for

  • Food & beverage$975100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$975 in reported general payments places this provider in the 75th percentile of 53 gerontology providers in Oregon.

See all gerontology providers in Oregon

Medicare billing

Part B allowed, 2024
$44,792
Medicare patients
173
Services billed
473

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban179$202,985
FarxigaDapagliflozin Propanediol51$45,387
EntrestoSacubitril/Valsartan46$44,367
XareltoRivaroxaban13$18,912
Metoprolol Succinate205$2,521
Rosuvastatin Calcium82$1,355
Losartan Potassium109$1,165
Torsemide35$626
Amiodarone Hcl36$484
Carvedilol53$441
Atorvastatin Calcium55$413
Spironolactone100$397
Amlodipine Besylate45$331
Olmesartan Medoxomil20$279
Ezetimibe17$251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$165$202,985179 claims
AstraZenecaFarxiga$51$45,38751 claims
NovartisEntresto$35$44,36746 claims
Johnson & JohnsonXarelto$48$18,91213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 53 gerontology providers in Oregon.

Other gerontology in Tualatin

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →